Morgan Stanley Codex Dna, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	N/A	-3,200 Reduced 94.73%	178 $0
Q2 2023 Aug 14, 2023	SELL	N/A	-1,728 Reduced 33.84%	3,378 $6,000
Q1 2023 May 15, 2023	BUY	$1.3 - $2.15 $4,501 - $7,445	3,463 Added 210.77%	5,106 $9,000
Q4 2022 Feb 14, 2023	SELL	$1.12 - $1.69 $5,729 - $8,646	-5,116 Reduced 75.69%	1,643 $1,000
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.36 $38,547 - $53,513	-22,675 Reduced 77.04%	6,759 $11,000
Q2 2022 Oct 27, 2022	BUY	$1.8 - $6.45 $30,051 - $107,682	16,695 Added 131.05%	29,434 $52,000
Q2 2022 Aug 15, 2022	BUY	$1.8 - $6.45 $30,051 - $107,682	16,695 Added 131.05%	29,434 $52,000
Q1 2022 Oct 27, 2022	SELL	$4.12 - $10.36 $68,783 - $172,960	-16,695 Reduced 56.72%	12,739 $68,000
Q1 2022 May 13, 2022	SELL	$4.12 - $10.36 $3,024 - $7,604	-734 Reduced 5.45%	12,739 $68,000
Q4 2021 Feb 14, 2022	BUY	$6.31 - $11.96 $31,846 - $60,362	5,047 Added 59.9%	13,473 $146,000
Q3 2021 Nov 15, 2021	BUY	$10.15 - $19.88 $85,523 - $167,508	8,426 New	8,426 $94,000

307

Ticker DNAY
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 29,518,200
Market Cap $54.6M
Description
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.